Sam Cobb is the founding CEO of AdAlta and has raised approximately $10M to date for AdAlta, through a combination of equity investment from angel investors and venture capital, grants and contract income. Sam has a number of years experience in business development and the commercialisation of early stage scientific technologies. Sam has a Bachelor of Science and a Masters of Intellectual Property Law.

Mick Foley is the founding CSO of AdAlta and well recognised internationally as an expert in identifying antibodies using the i-body platform to difficult targets such as GPCRs. Mick is a key inventor of the anti-fibrotic i-body and will play a major role in the scientific evaluation and pre-clinical development relating to this project.